Interleukin-2-BAX
Latest Information Update: 26 Apr 2002
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Transplant rejection
Most Recent Events
- 19 Feb 1999 New profile
- 19 Feb 1999 Preclinical development for Autoimmune disorders in Israel (Unknown route)
- 19 Feb 1999 Preclinical development for Transplant rejection in Israel (Unknown route)